--- title: "Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap" type: "News" locale: "en" url: "https://longbridge.com/en/news/288550080.md" description: "Hims & Hers Health completed its acquisition of Eucalyptus, expanding operations into Australia, Japan, Germany, Canada, and the UK. This move transitions the company from a US-centric model to a global digital health platform with established local infrastructure. While the stock trades slightly above analyst targets, it is valued significantly below fair value estimates. Investors are advised to monitor integration progress, regulatory compliance, and capital allocation as the company diversifies geographically." datetime: "2026-06-03T09:26:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288550080.md) - [en](https://longbridge.com/en/news/288550080.md) - [zh-HK](https://longbridge.com/zh-HK/news/288550080.md) --- # Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap - Hims & Hers Health (NYSE:HIMS) has completed its acquisition of Eucalyptus. - The deal formally extends Hims & Hers into Australia, Japan, and Germany, and expands its presence in Canada and the UK. - The acquisition brings established local platforms, clinical infrastructure, and customer bases in several international markets. Hims & Hers Health operates a direct to consumer digital health platform focused on areas such as primary care, mental health, and wellness. With Eucalyptus now part of the group, the company adds licensed operations and on the ground healthcare relationships in multiple countries, which can matter for regulators, prescribers, and patients. For investors, this represents a move from a primarily US centered operation to a business with a broader international footprint. Key questions from here include how quickly Hims & Hers can integrate Eucalyptus technology and clinical operations, and how effectively it can tailor offerings to local regulations and consumer preferences. The acquisition also introduces more geographic diversification, which can influence growth mix, marketing spend, and capital allocation as management prioritizes new and existing markets. Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health. NYSE:HIMS Earnings & Revenue Growth as at Jun 2026 2 things going right for Hims & Hers Health that this headline doesn't cover. ### Quick Assessment - **⚖️ Price vs Analyst Target**: At US$27.51, Hims & Hers trades about 3.4% above the US$26.61 analyst consensus target, which is within a 10% band. - **✅ Simply Wall St Valuation**: Simply Wall St estimates the stock is trading 58.6% below its fair value, indicating a valuation gap. - **✅ Recent Momentum**: The stock is up 0.4% over the last 30 days, reflecting slightly positive short term performance. To assess whether it is the right time to buy, sell or hold Hims & Hers Health, you can refer to Simply Wall St's company report for the latest analysis of Hims & Hers Health's Fair Value. ### Key Considerations - 📊 The Eucalyptus deal turns Hims & Hers into a broader international platform, so your thesis now depends more on multi country execution, not just the US. - 📊 Monitor how management discusses integration timelines, local regulatory approvals, marketing spend by region, and any updates to margin or capital allocation plans. - ⚠️ The stock has been classified as highly volatile over the past 3 months, which can magnify market reactions if integration or regulatory updates disappoint. ### Dig Deeper For a more complete view, including additional risks and potential rewards, visit the complete Hims & Hers Health analysis. You can also review the community page for Hims & Hers Health to see how other investors believe this latest news may affect the company's narrative. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if Hims & Hers Health might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) ## Related News & Research - [Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock](https://longbridge.com/en/news/288868732.md) - [Hims & Hers Stock Jumps: What's Happening Today?](https://longbridge.com/en/news/288746645.md) - [BUZZ-US FDA's peptide classification review could expand Hims & Hers' market share, Canaccord says](https://longbridge.com/en/news/288560581.md) - [Hims & Hers Amends Revolving Credit Agreement With JPMorgan to Support Eucalyptus Deal](https://longbridge.com/en/news/288405120.md) - [Granite Construction (GVA) Valuation Check After New Contracts And US$600 Million Notes Offering](https://longbridge.com/en/news/288933255.md)